Chimeric Antigen Receptor (CAR)-T cell therapies are treatments in which a patient's T cells are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added in the laboratory.
In multiple myeloma, currently approved CAR-T therapies are targeted against B-cell maturation antigen (BCMA). Although research suggests that CD229 might be a good future target — potentially providing longer-lasting responses.
More information about our CAR-T Cell Therapy syndicated study in the context of multiple myeloma?
- Background information on CAR-T
- Research design and methodology
- Research timeline and investment
Fill in the form and we will be in touch shortly. 👉
Go further with the data and discover an example of a Digital & Interactive Dashboard (DID) created by APLUSA
We take here the example of a patient share tracker in Cancer X syndiTrackTM.
The dashboard is built around 6 variables: the country, the treatment start date, the treatment line, the product or regimen, risk factors and market share.
In total, there are many advantages of using this DID:
- your data is available online and can be easily shared within your organization,
- you can create your own views instead of manipulating a large number of powerpoint slides,
- you always have the latest data available, no update problems,
- the data is available on your dashboard much earlier in the data collection,
- the report will be more focused on key insights and storytelling than on data production.
👇 Test our live demo here! 👇